Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells

• Published in: Gynecologic oncology Vol. 98; no. 1; pp. 45 - 53
• Main Authors: Lee, Keun-Ho, Yim, Eun-Kyoung, Kim, Chan-Joo, Namkoong, Sung-Eun, Um, Soo-Jong, Park, Jong-Sup
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2005
• Subjects: Antineoplastic Agents, Phytogenic - pharmacology; Cell Cycle - drug effects; Cell Cycle - genetics; Cell Cycle Proteins - analysis; Cell Cycle Proteins - biosynthesis; Cell Cycle Proteins - genetics; Cervical carcinoma; Electrophoresis, Gel, Two-Dimensional; Female; HeLa Cells; HPV; Humans; Mitotic checkpoint protein BUB3; Paclitaxel; Paclitaxel - pharmacology; Poly-ADP-Ribose Binding Proteins; Proteomics; RNA, Small Interfering - genetics; Small interfering RNA (siRNA); Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods; Tetrazolium Salts; Thiazoles; Transfection; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - metabolism; Uterine Cervical Neoplasms - pathology; Small interfering RNA (siRNA); Cervical carcinoma; Paclitaxel; Proteomics; HPV; Mitotic checkpoint protein BUB3
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2005.04.010

Paclitaxel (Taxol®), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used in the treatment of ovarian, lung and breast cancer. At present, there is little information regarding the anti-cancer mechanism of paclitaxel against cervical carcinoma cells. We thus tried to show the anti-cancer effect of paclitaxel on cervical carcinoma cell line carrying HPV by using a proteomic analysis and to investigate the mechanism of actions. We treated paclitaxel to cervical carcinoma cells and then carried out MTT assay to observe the anti-proliferate activity. Using proteomics analysis including two-dimensional (2-DE) gel electrophoresis and MALDI-TOF-MS, we tried to find the anti-proliferate activity-related proteins. Among them, paclitaxel treatment suppressed the expression of the mitotic checkpoint protein BUB3. Functional proteomic analysis by small interfering RNA (siRNA) targeting was tried to illuminate a role of mitotic checkpoint protein BUB3 in cell cycle progression. The cytotoxicity effects of paclitaxel were determined in HPV-16 positive CaSki, HPV-18 positive HeLa and HPV-negative C33A cervical carcinoma cell lines. Using efficient proteomics methods including 2-DE/MALDI-TOF-MS, we identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells. Paclitaxel treatment elevated mainly apoptosis-related, immune response-related and cell cycle check point-related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Paclitaxel showed anti-proliferate activity through the membrane death receptor (DR)-mediated apoptotic pathway involving activation of caspase-8 with a TRAIL-dependent fashion as well as the mitochondrial-mediated pathway involving down-regulation of bcl-2 by cytochrome c release. Furthermore, we found siRNA-induced BUB3 knock down on cell cycle progression blocked by cell cycle arrest after paclitaxel treatment. The proteome profiling technique provided a broad-base and effective approach for the identification of protein changes induced by paclitaxel and showed anti-proliferate activity through the membrane death receptor-mediated apoptotic pathway, the mitochondrial-mediated pathway. This study shows the power of proteomic profiling with functional analysis using RNAi technology for the discovery of novel molecular targets and a better understanding of the actions of paclitaxel at the molecular level in cervical carcinoma cells.